Posted by Michael Wonder on 21 Dec 2024
Gilead submits new drug application to US FDA for twice-yearly lenacapavir for HIV prevention
19 December 2024 - Lenacapavir named 2024 “Breakthrough of the Year” by Science Magazine.
Gilead today announced the company completed new drug application submissions to the US FDA seeking approval of an investigational use of lenacapavir—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis.
